Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2026
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this report focuses on corporate events rather than financial performance data.
Material Changes and Corporate Events
- Scientific Presentation: The company announced a Late-Breaker Oral Presentation at the American Academy of Neurology (AAN) meeting (Exhibit 99.1).
- Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on financial risks, or details on contingencies beyond the announcement of the scientific presentation.
Investor Verification Checklist
- Verify the content and clinical data presented in the Late-Breaker Oral Presentation at the AAN (refer to Exhibit 99.1).
- Review the referenced Form S-8 and Form F-3 registration statements for details on equity compensation plans and potential capital raises.
- Confirm the company's current cash runway and burn rate, as this filing does not disclose financial status.